What Cinnarizine Treats: Main Uses and Benefits

Cinnarizine may be part of symptomatic management across several key therapeutic domains related to systemic imbalance and motion. The medication is commonly used to address symptoms related to inner ear disorders, including the severe spinning sensation of vertigo and general unsteadiness, as well as being applied to manage symptoms associated with motion sensitivity like nausea and vomiting (travel sickness). It is also relevant in conditions such as Ménière's disease where symptoms cluster with tinnitus (ringing in the ears).

---

Vertigo and Balance Disturbances

Cinnarizine supports the management of these episodic or recurrent symptoms, providing support that helps maintain a sense of stability and functional comfort during periods when symptoms become more noticeable.

---

Prevention and Symptom Support

The medication contributes to providing supportive relief when symptoms interfere with routine activities. Cinnarizine is commonly applied to address symptom clusters that may become intense or disruptive, and is used when short-term symptomatic assistance is needed for travel contexts or episodes of increased discomfort.

---

Quick Fact: Relief for Balance Disturbances

The medication is commonly used to help manage symptoms related to inner ear disorders, contributing to easing the overall symptom load during symptomatic periods.

Eligibility Map: Who can and cannot use Cinnarizine

The eligibility profile for Cinnarizine is strictly defined by regulatory documents, establishing populations for approved use, conditional use, and absolute prohibition. Adults and children aged 5 years and over are generally eligible for use under standard labeled conditions.

Contraindicated Populations (Must Not Use)	Restricted Populations (Use with Caution)
Patients with known hypersensitivity to Cinnarizine	Older adults (increased susceptibility to effects)
Patients with established Parkinson's disease or parkinsonism	Patients with mild to moderate hepatic or renal impairment
Patients with porphyria	Patients with hypotension or conditions aggravated by anticholinergic effects
Patients with severe hepatic or renal impairment

Use is officially not recommended for children under 5 years of age as safety is not established. Similarly, it is not recommended during pregnancy or lactation because safety data are either absent or insufficient for confirmation in these groups, as stated in regulatory labeling. The medicine is also strictly contraindicated in patients with conditions like angle-closure glaucoma.

Interactions with other medicines and products

Cinnarizine's interaction profile is primarily defined by pharmacodynamic effects that potentiate central nervous system activity, as documented in official government regulatory information.

Documented Pharmacodynamic Interactions

Interaction Type	Interacting Substances/Category	Official Outcome Statement
Potentiation of Sedation	Alcohol and Central Nervous System (CNS) Depressants (e.g., Opioid Analgesics, Hypnotics, Anxiolytics, Antipsychotics)	Co-administration may result in an enhancement of sedative effects [1.4, 1.5].
Additive Antimuscarinic Action	Antimuscarinic drugs (e.g., Atropine-like agents, certain Antidepressants)	Concurrent use is associated with an additive antimuscarinic action [2.2].
Sensory Masking	Ototoxic drugs (e.g., Aminoglycoside antibiotics)	May mask the warning signs of ototoxicity caused by co-administered drugs [2.2].

Official Constraints and Timing Rules

Official labeling contains specific constraints related to administration and diagnostic procedures. Cinnarizine may prevent a positive reaction to dermal reactivity indicators and must therefore be discontinued four days prior to dermal reactivity skin testing [1.6, 1.7]. To mitigate the occurrence of epigastric discomfort, official guidance recommends taking the medication after meals [1.3]. While no absolute contraindications based purely on drug-drug interaction are typically listed, the risk of enhanced sedation is a key regulatory focus [1.5].

Cinnarizine acts through multiple, interconnected mechanistic domains to influence specific signaling pathways, primarily targeting the vestibular system and vascular smooth muscle.

---

Modulation of Calcium Channels

Cinnarizine primarily functions as an inhibitor of L-type and T-type voltage-gated calcium channels in smooth muscle cells. This action limits the influx of calcium ions, reducing smooth muscle contraction and resulting in vasorelaxation, which modifies local hemodynamic parameters.

---

Receptor Antagonism

The drug engages mechanisms involving histamine H1 receptors and, to a lesser extent, muscarinic acetylcholine receptors. By blocking these receptors, cinnarizine influences the signaling of the vestibular system and the central nervous system, thereby modifying afferent signal transmission.

---

Neurotransmitter Modulation

Cinnarizine also acts as an antagonist at dopamine D2 receptors. This interaction modifies processes associated with sensory input and motion-related signals, further influencing activity within targeted neural circuits.

Cinnarizine is an orally administered pharmaceutical preparation, generally available as a mathbf15 mg or mathbf25 mg tablet, or as a mathbf75 mg capsule. The medicine is intended for oral use only. The precise regimen is determined by the condition and individual clinical requirements.

For managing balance disorders, the standard adult approach is a divided dose of mathbf25 mg taken three times daily (TID). Alternatively, some formulations allow for a mathbf75 mg dose taken once daily. The overall mathbf24-hour intake for any use must not exceed the specified mathbf225 mg maximum daily dose.

The administration of Cinnarizine for motion sickness prevention follows an intermittent schedule. The initial dose of mathbf25 mg or mathbf30 mg is taken mathbf30 minutes to mathbf2 hours before the start of a journey, and subsequent doses may be repeated every mathbf6 to mathbf8 hours as needed during travel. To reduce the potential for gastrointestinal irritation, the medicine should preferably be taken with or immediately after food.

Treatment duration varies; use for motion sensitivity is short-term, while therapy for balance disorders may involve continuous maintenance over several months. For children aged mathbf5 to mathbf12, the dosage is generally half the adult dose. If a dose is missed, a minimum interval of mathbf8 hours must be maintained before the next dose is taken.

Research evidence / Overview of studies for Cinnarizine

---

## Evidence for use in Vertigo and Balance Disorders

Clinical research on Cinnarizine includes multiple Randomized Controlled Trials (RCTs) and subsequent meta-analyses that consolidate findings from these comparisons. These studies were designed to explore how Cinnarizine compares to either a placebo or other active treatments, relevant in trials assessing short-term or episodic symptom patterns in vestibular vertigo and other balance disorders. Studies examined how symptoms are measured, including changes in severity and frequency using validated symptom scores, and monitored objective measures of balance related to the inner ear mechanism.

Research explored Cinnarizine in conditions characterized by fluctuating or episodic manifestations. Studies report how symptoms evolved in the observed populations, highlighting changes measured during the study period. This evidence contributes to understanding symptom patterns over defined time intervals, often up to 4 weeks.

However, a key limitation is that many of the most extensive, high-quality studies were conducted during periods of increased symptom activity and evaluated Cinnarizine as part of a fixed-dose combination with another agent, Dimenhydrinate. This often limits definitive conclusions when Cinnarizine is used alone (monotherapy). Additionally, comparative evidence against some other standard treatments was observed in some studies to be mixed or inconsistent.

---

## Evidence for use in Motion Sickness

Research scenarios involving outcomes related to physical discomfort were the primary focus of the evidence base for motion sickness. Research includes double-blind, randomized, placebo-controlled trials conducted with healthy volunteers who are susceptible to motion. These studies explored outcomes describing episodic or acute changes, primarily focusing on outcomes related to systemic or functional imbalance. Some research also used controlled, induced-motion models to observe temporary physiological imbalance.

Studies monitored outcomes related to outcomes related to physical discomfort in research scenarios involving temporary physiological imbalance. Findings help contextualize how symptoms evolved in the observed populations, based on outcomes tracked over short timeframes.

Research is primarily focused on outcomes related to systemic or functional imbalance, and research exploring short-term symptom changes once active motion sickness has already begun is limited. Furthermore, while the agent was studied for motion sickness, comparative evidence is lacking for some comparisons against alternative prophylactic options in specific, high-exposure settings.

Key Studies & References

1. Betahistine or cinnarizine with or without dimenhydrinate for Ménière's disease/syndrome and symptoms of vestibular vertigo and/or tinnitus - HTA Report
2. Public Assessment Report National Procedure Cinnarizine 15mg Tablets

Common questions about Cinarizin (FAQ)

Q: Is Cinarizin the same type of medicine as meclizine or dimenhydrinate?

A: Cinnarizine is officially classified as an H1-antagonist, a type of antihistamine, and a calcium channel blocker. This dual action gives it a pharmacological profile that is distinct from medicines that only act as antihistamines. Official information notes Cinnarizine is not approved for use by the FDA in the United States, where meclizine is often used as a first-line choice for acute peripheral vertigo.

Q: Is Cinarizin known to interact with common pain relievers?

A: Official regulatory documents indicate that co-administration with Opioid Analgesics, which are a specific type of pain reliever, may lead to an enhancement of sedative effects. Regulatory warnings focus on the enhancement of sedative effects when combined with CNS depressants, which includes Opioid Analgesics.

Q: Can Cinarizin be taken on an empty stomach?

A: Regulatory guidance recommends that Cinnarizine should preferably be taken with or immediately after food. This recommendation is made to help mitigate the potential for gastrointestinal irritation, as stated in regulatory guidance for administration context.

Q: Can Cinarizin be used during air travel to prevent motion sickness?

A: Yes, Cinnarizine is approved for the prophylaxis (prevention) of motion sickness, which includes various types of travel. Official instructions specify that a preventive dose should be taken before the start of a journey, with subsequent doses allowed every six to eight hours during travel, as needed.

Q: Are there high-level descriptions of Cinarizin's safety profile during pregnancy?

A: Use of Cinnarizine during pregnancy is officially not recommended. This is due to regulatory statements indicating that safety data are absent or insufficient for confirmation in this group.

Q: Can Cinarizin cause changes in appetite or weight?

A: Official safety documents list Weight Increased as a Common adverse reaction, meaning it is reported in more than 1 out of 100 patients. Regulatory information focuses on weight gain as a reported side effect.

Q: What is the typical timeframe for a follow-up appointment after starting Cinnarizine?

A: Official prescribing information does not typically mandate a specific timeframe for follow-up or check-up appointments. Patient information leaflets often note that if symptoms do not show improvement within 2 to 3 days of starting treatment, medical consultation may be advised. Clinical trials for vestibular disorders often observe symptom changes within the first two weeks.

Q: Can Cinarizin cause dry mouth or constipation?

A: Cinnarizine has properties associated with antimuscarinic action. However, dry mouth and constipation are not listed as common or uncommon adverse reactions in the core safety documents provided.

Q: What is the consensus in the scientific literature regarding Cinarizin for vertigo?

A: Clinical research includes Randomized Controlled Trials (RCTs) and meta-analyses that have explored Cinnarizine's use for vestibular vertigo. Regulatory summaries note a limitation: that many high-quality studies evaluated Cinnarizine as part of a fixed-dose combination with Dimenhydrinate, which can complicate definitive conclusions when Cinnarizine is used alone.

Q: Is Cinarizin a prescription drug or is it available over the counter in most places?

A: The regulatory classification of Cinnarizine varies significantly depending on the country. In many regions, it is available over-the-counter and can be purchased directly from a pharmacy. However, in other regions or for certain medical conditions, it is classified as a prescription-only medication.

Q: Are there research studies comparing Cinarizin to placebo for balance issues?

A: Regulatory summaries of the evidence base indicate that clinical research includes Randomized Controlled Trials (RCTs) designed to explore how Cinnarizine compares to either a placebo (an inactive treatment) or other active treatments for vestibular vertigo and balance disorders.

Q: What types of interactions are reported between Cinnarizine and alcohol?

A: Official regulatory documents specifically report that co-administration (taking them at the same time) with alcohol may result in an enhancement of sedative effects.

Q: What is the expected duration of effect for a single dose of Cinarizin?

A: Official information suggests that a single dose may take up to 4 hours to reach its full effect. Pharmacokinetic data indicates that its protective effects against motion sickness may be sustained for 5 to 7 hours post-dose, which informs the spacing of repeat doses.

Q: What is the difference between Cinarizin and a drug like Betahistine?

A: Cinnarizine is classified as an H1-antagonist and a calcium channel blocker. Betahistine is a different type of medicine known as a histamine analogue. It works differently in the body, specifically with a different pattern of action on histamine receptors, which distinguishes its pharmacological mechanism from Cinnarizine.

Q: Is Cinarizin metabolized by the liver, and what does that imply for drug interactions?

A: Pharmacokinetic data confirms that Cinnarizine is extensively metabolized in the body, primarily in the liver via the CYP2D6 enzyme. This specific metabolic pathway is a key consideration for its potential interactions with other medicines that are also processed by or affect the same liver enzyme.

Q: Can Cinarizin interact with medicines used to treat anxiety?

A: Official warnings caution that Cinnarizine may enhance the sedative effects when used concomitantly with Central Nervous System (CNS) Depressants. This category includes medicines used to treat anxiety, such as Anxiolytics, and the combination may increase drowsiness.

Q: Has Cinarizin been researched for any uses other than motion sickness and balance problems?

A: Beyond its primary uses for motion sickness and balance, Cinnarizine is also classified as influencing blood vessel tone due to its calcium channel blocking properties. In some regulatory jurisdictions, it is also indicated for the management of peripheral circulatory disorders.

Q: Are there studies about Cinnarizine's effect on memory or concentration?

A: Official warnings advise that the medicine may lead to drowsiness and impaired concentration. This is a potential effect that may be aggravated when Cinnarizine is taken alongside alcohol or other Central Nervous System depressants.

Q: What is the average time it takes for Cinnarizine to be fully eliminated from the body?

A: Pharmacokinetic data from regulatory documents indicates that the elimination half-life for Cinnarizine ranges from 4 to 24 hours. This time frame represents the period required for the body to reduce the amount of the drug by half. Elimination occurs primarily through the faeces and, to a lesser extent, the urine.

Q: Why is Cinarizin not widely available in the United States compared to Europe?

A: Cinnarizine is not approved for use in the United States by the FDA. In other regions, like Canada, regulatory decisions have sometimes involved a lack of sufficient supportive information to confirm the validity of specific patient-reported outcome measures used in clinical trials, which limits its widespread availability.

Q: How does the structure of Cinarizin relate to other antihistamines?

A: Cinnarizine is structurally related to traditional antihistamines but is distinct due to its unique pharmacological classification. It functions as both an H1-receptor antagonist (a type of antihistamine) and a non-selective calcium channel blocker, which is not typical for most antihistamine agents.

Q: What are the main research themes investigated in recent Cinnarizine studies?

A: Regulatory summaries indicate research has focused on themes such as using validated symptom scores to measure changes in the severity and frequency of symptoms in vestibular disorders. Research also includes observing outcomes in induced-motion models—controlled experiments used to study motion sickness in healthy volunteers.

Q: Does Cinnarizine interact with herbal supplements?

A: Official patient information advises caution, stating that there is not enough information to confirm whether other complementary medicines, herbal remedies, and supplements are safe to take with Cinnarizine. Regulatory patient information notes that consultation with a pharmacist may be helpful regarding supplements that could cause effects like sleepiness or dry mouth.

How to Store and Dispose of Cinnarizine

Official regulatory documentation mandates specific environmental and handling controls to maintain the integrity of Cinnarizine tablets.

Storage Requirements

The medicine must be stored at a temperature below 30 C and protected from light. To prevent accidental ingestion, the product must be kept out of the sight and reach of children and, in some cases, stored locked up. The medication should remain in its original package and the container must be kept tightly closed in a well-ventilated location.

Disposal Instructions

Unused or expired Cinnarizine must be disposed of in accordance with local requirements. Official regulations prohibit discarding the medicine through wastewater (e.g., sinks or toilets) or general household waste. Patients are advised to consult their pharmacist for appropriate disposal methods that comply with regional and national environmental regulations.